Difference between revisions of "Dactinomycin (Cosmegen)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Wilms' tumor" to "Wilms tumor") |
Warner-admin (talk | contribs) m (Text replacement - "Ewing's sarcoma" to "Ewing sarcoma") |
||
Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Endometrial cancer]] | *[[Endometrial cancer]] | ||
− | *[[Ewing | + | *[[Ewing sarcoma]] |
*[[Gestational trophoblastic neoplasia]] | *[[Gestational trophoblastic neoplasia]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] |
Revision as of 16:45, 1 March 2019
General information
Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Endometrial cancer
- Ewing sarcoma
- Gestational trophoblastic neoplasia
- Osteosarcoma
- Rhabdomyosarcoma
- Wilms tumor
Patient drug information
- Dactinomycin (Cosmegen) patient drug information (Chemocare)[3]
- Dactinomycin (Cosmegen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/10/1964: Initial FDA approval
Also known as
- Generic names: AC-DE, actinomycin D
- Brand names: Cosmegen, Dacmozen, Lyovac
References
Categories:
- Drugs
- Intravenous medications
- Vesicant chemotherapy
- DNA synthesis inhibitors
- Endometrial cancer medications
- Ewing sarcoma medications
- Gestational trophoblastic neoplasia medications
- Osteosarcoma medications
- Soft tissue sarcoma medications
- Wilms tumor medications
- FDA approved in 1964
- WHO Essential Cancer Medicine